Xenon Pharmaceuticals Inc

NASDAQ:XENE   11:31:15 AM EDT
11.02
-0.26 (-2.31%)
Products

Xenon Pharmaceuticals Receives FDA Feedback And Is On Track To Initiate Phase 3 Clinical Trial For The Treatment Of Kcnq2-Dee

Published: 10/08/2020 12:55 GMT
Xenon Pharmaceuticals Inc (XENE) - Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate Xen496 Phase 3 Clinical Trial for the Treatment of Kcnq2-dee Before Year-end.
Xenon Pharmaceuticals Inc - on Track to Initiate Xen496 Phase 3 Clinical Trial in Pediatric Patients With Kcnq2-dee Before Year-end.
Xenon Pharmaceuticals - Got Positive Opinion From Comp of Ema Which Recommends Granting of Orphan Medicinal Product Designation for Xen496.
Xenon Pharmaceuticals Inc - Expect to Initiate Epik Study Before Year-end.